Molecular docking studies revealed that DMAKO-20 selectively interacts with CYP1B1, demonstrating strong binding affinity and tumor-specific oxidation, which enhances its anticancer effects [85,86,87,88]. This evidence concerns the gene CYP1B1 and neoplasm.